株式会社フェニックスバイオ

Species differences in liver accumulation and metabolism of nucleotide prodrug sofosbuvir

Wang, T. Babusis, D. Park, Y. Niu, C. Kim, C. Zhao, X. Lu, B. Ma, B. Muench, R. C. Sperger, D. Ray, A. S. Murakami, E.

Drug Metab Pharmacokinet. 2020 Jun;35(3):334-340. doi: 10.1016/j.dmpk.2020.04.333. Epub 2020 Apr 16.

READ MORE(PUB MED)

Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection

Cheng, X. Uchida, T. Xia, Y. Umarova, R. Liu, C. J. Chen, P. J. Gaggar, A. Suri, V. Mucke, M. M. Vermehren, J. Zeuzem, S. Teraoka, Y. Osawa, M. Aikata, H. Tsuji, K. Mori, N. Hige, S. Karino, Y. Imamura, M. Chayama, K. Liang, T. J.

J Clin Invest. 2020 Mar 12. pii: 135616. doi: 10.1172/JCI135616.

READ MORE(PUB MED)

Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice

Osawa, M. Uchida, T. Imamura, M. Teraoka, Y. Fujino, H. Nakahara, T. Ono, A. Murakami, E. Kawaoka, T. Miki, D. Tsuge, M. Hiramatsu, A. Abe-Chayama, H. Hayes, C. N.

J Gen Virol. 2019 Jul;100(7):1123-1131.

READ MORE(PUB MED)

Humanized Mouse Models for the Study of Hepatitis C and Host Interactions

Yong, K. S. M. Her, Z. Chen, Q.

Cells. 2019 Jun 17;8(6). pii: cells8060604.

READ MORE(PUB MED)

Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of HCV-infected Cells and Liver to Identify Pathways Associated With Disease Development

Lupberger, J. Croonenborghs, T. Roca Suarez, A. A. Van Renne, N. Juhling, F. Oudot, M. A. Virzi, A. Bandiera, S. Jamey, C. Meszaros, G. Brumaru, D. Mukherji, A. Durand, S. C. Heydmann, L. Verrier, E. R. El Saghire, H. Hamdane, N. Bartenschlager, R. Fereshetian, S. Ramberger, E. Sinha, R. Nabian, M. Everaert, C. Jovanovic, M. Mertins, P. Carr, S. A. Chayama, K. Dali-Youcef, N. Ricci, R. Bardeesy, N. M. Fujiwara, N. Gevaert, O. Zeisel, M. B. Hoshida, Y. Pochet, N. Baumert, T. F.

Gastroenterology. 2019 Apr 9. pii: S0016-5085(19)35670-7. doi: 10.1053/j.gastro.2019.04.003.

READ MORE(PUB MED)

HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response

Hamdane, N. Juhling, F. Crouchet, E. El Saghire, H. Thumann, C. Oudot, M. A. Bandiera, S. Saviano, A. Ponsolles, C. Roca Suarez, A. A. Li, S. Fujiwara, N. Ono, A. Davidson, I. Bardeesy, N. Schmidl, C. Bock, C. Schuster, C. Lupberger, J. Habersetzer, F. Doffoel, M. Piardi, T. Sommacale, D. mamura, M. Uchida, T. Ohdan, H. Aikata, H. Chayama, K. Boldanova, T. Pessaux, P. Fuchs, B. C. Hoshida, Y. Zeisel, M. B. Duong, F. H. T. Baumert, T. F.

Gastroenterology. 2019 Mar 2. pii: S0016-5085(19)32506-5. doi: 10.1053/j.gastro.2019.02.038.

READ MORE(PUB MED)

Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection

Ishida, Y. Kakuni, M. Bang, B. R. Sugahara, G. Lau, D. T. Tateno-Mukaidani, C. Li, M. Gale, M., Jr. Saito, T.

J Interferon Cytokine Res. 2019 Mar;39(3):133-146. doi: 10.1089/jir.2018.0103.

READ MORE(PUB MED)

Ribonucleotide reductase M2 promotes RNA replication of hepatitis C virus by protecting NS5B protein from hPLIC1-dependent proteasomal degradation

Kitab, B. Satoh, M. Ohmori, Y. Munakata, T. Sudoh, M. Kohara, M. Tsukiyama-Kohara, K.

J Biol Chem. 2019 Feb 12. pii: RA118.004397. doi: 10.1074/jbc.RA118.004397.

READ MORE(PUB MED)

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure

Teraoka, Y. Uchida, T. Imamura, M. Hiraga, N. Osawa, M. Kan, H. Saito, Y. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

J Gen Virol. 2018 Jun 19. doi: 10.1099/jgv.0.001091.

READ MORE(PUB MED)

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

Teraoka, Y. Uchida, T. Imamura, M. Osawa, M. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

Biochem Biophys Res Commun. 2018 Jun 2;500(2):152-157.

READ MORE(PUB MED)

Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

Rolt, A. Le, D. Hu, Z. Wang, A. Q. Shah, P. Singleton, M. Hughes, E. Dulcey, A. E.He, S. Imamura, M. Uchida, T. Chayama, K. Xu, X. Marugan, J. J. Liang, T. J.

J Infect Dis. 2018 Jan 24. pii: 4823490. doi: 10.1093/infdis/jiy039.

READ MORE(PUB MED)

A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage

Reddy, B. U. Mullick, R. Kumar, A. Sharma, G. Bag, P. Roy, C. L. Sudha, G. Tandon, H. Dave, P. Shukla, A. Srinivasan, P. Nandhitha, M.Srinivasan, N. Das, S.

Antiviral Res. 2017 Dec 7;150:47-59.

READ MORE(PUB MED)

Hepatitis C replication inhibitors that target the viral NS4B protein

Miller, J. F. Chong, P. Y. Shotwell, J. B. Catalano, J. G. Tai, V. W. Fang, J. Banka, A. L. Roberts, C. D. Youngman, M. Zhang, H. Xiong, Z. Mathis, A. Pouliot, J. J. Hamatake, R. K. Price, D. J. Seal, J. W., 3rd Stroup, L. L. Creech, K. L. Carballo, L. H. Todd, D. Spaltenstein, A. Furst, S. Hong, Z. Peat, A. J.

J Med Chem. 2014 Mar 13;57(5):2107-20

READ MORE(PUB MED)

Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus

Hamana, A. Takahashi, Y. Uchida, T. Nishikawa, M. Imamura, M. Chayama, K. Takakura, Y.

Antiviral Res. 2017 Aug 31;146:130-138.

READ MORE(PUB MED)

Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells

Chida, T. Ito, M. Nakashima, K. Kanegae, Y. Aoshima, T. Takabayashi, S. Kawata, K. Nakagawa, Y. Yamamoto, M. Shimano, H. Matsuura, T. Kobayashi, Y. Suda, T. Suzuki, T.

Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.

READ MORE(PUB MED)

Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus

Miyaki, E. Hiraga, N. Imamura, M. Uchida, T. Kan, H. Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Serikawa, M. Aikata, H. Ochi, H. Ishida, Y. Tateno, C. Ohdan, H. Chayama, K.

PLoS One. 2017 Mar 2;12(3):e0172412.

READ MORE(PUB MED)

Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology

Uchida, T. Imamura, M. Kan, H. Hiraga, N. Hayes, C. N. Tsuge, M. Abe-Chayama, H. Aikata, H. Makokha, G. N. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

J Gen Virol. 2017 Jan 28. doi: 10.1099/jgv.0.000726.

READ MORE(PUB MED)

Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing

Kan, H. Imamura, M. Uchida, T. Hiraga, N. Hayes, C. N. Tsuge, M. Abe, H. Aikata, H. Makokha, G. N. Chowdhury, S. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

J Infect Dis. 2016 Sep 20. pii: jiw437.

READ MORE(PUB MED)

Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy

DebRoy, S. Hiraga, N. Imamura, M. Hayes, C. N. Akamatsu, S. Canini, L. Perelson, A. S. Pohl, R. T. Persiani, S. Uprichard, S. L. Tateno, C. Dahari, H. Chayama, K.

J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12551.

READ MORE(PUB MED)

Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir andBMS-788329 combination therapy in human hepatocyte chimeric mice

Uchida, T. Hiraga, N. mamura, M. Yoshimi, S. Kan, H. Miyaki, E. Tsuge, M. Abe, H. Hayes, C. N. Aikata, H. Ishida, Y. Tateno, C. Ellis, J. D. Chayama, K.

Virus Res. 2015 Nov 10. pii: S0168-1702(15)30117-9. doi: 10.1016/j.virusres.2015.11.010.

READ MORE(PUB MED)

研究開発

Species differences in liver accumulation and metabolism of nucleotide prodrug sofosbuvir

Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection

Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice

Humanized Mouse Models for the Study of Hepatitis C and Host Interactions

Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of HCV-infected Cells and Liver to Identify Pathways Associated With Disease Development

HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response

Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection

Ribonucleotide reductase M2 promotes RNA replication of hepatitis C virus by protecting NS5B protein from hPLIC1-dependent proteasomal degradation

Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure

Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice

Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection

A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage

Hepatitis C replication inhibitors that target the viral NS4B protein

Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus

Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells

Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus

Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology

Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing

Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy

Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir andBMS-788329 combination therapy in human hepatocyte chimeric mice